Skip to main content

Table 3 Summary of cardiovascular irAEs

From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

Case

Cardiovascular complications

Age (years), sex

Malignancy

ICI

Days from first ICI administration to cardiovascular irAEs

Days from non-cardiovascular irAEs to cardiovascular irAEs

Management

Outcome

1

Paf

66, M

Renal cancer

Nivolumab

64

15

Pilsicainide

Survived

2

Paf

71, M

NSCLC

Pembrolizumab

35

25

Anticoagulant therapy

Survived

3

AFL

44, F

NSCLC

Nivolumab

4

(-)

Bisoprolol

Cancer death

4

PSVT

72, F

NSCLC

Nivolumab

89

65

Bisoprolol

Cancer death

5

VT

71, M

Melanoma

Pembrolizumab

6

(-)

Catheter ablation

Survived

6

AP

74, M

NSCLC

Nivolumab

201

(-)

PCI

Survived

7

AP

79, M

NSCLC

Nivolumab

1102

986

Nitrous acid

Survived

8

VSP

58, M

Melanoma

Pembrolizumab

294

204

Nitrous acid

Survived

9

Pericardial effusion

45, M

NSCLC

Pembrolizumab

59

58

Pericardial drainage

Cancer death

10

Pericardial effusion

45, M

NSCLC

Pembrolizumab

253

246

Pericardial drainage

Cancer death

11

PE

77, F

NSCLC

Pembrolizumab

161

(-)

Anticoagulant therapy

Survived

12

HF

71, M

NSCLC

Nivolumab

72

(-)

Diuretics

Cancer death

13

Fulminant myocarditis

59, M

Melanoma

Ipilimumab

 → 

Nivolumab

495

418

MCS + PSL pulse

Survived from myocarditis, Cancer death

14

Myocardial vasculitis

79, F

Melanoma

Pembrolizumab

263

74

PSL

Survived

  1. ICI immune checkpoint inhibitor, Paf paroxysmal atrial fibrillation, AFL atrial flutter, PSVT paroxysmal supraventricular tachycardia, VT ventricular tachycardia, AP angina pectoris, VSP vasospastic angina, PE pulmonary embolism, HF heart failure, NSCLC non-small cell lung cancer, PCI percutaneous coronary intervention, MCS mechanical circulatory support, PSL prednisolone, Other abbreviations as in Table 1